Coherus Oncology (CHRS) · tagmokitug + toripalimab
Later window · A neutral label from comparing the two stated windows. It says nothing about the program’s results.
Before
Stated timing: mid-2026
● The Phase 1b tagmokitug/toripalimab combination dose optimization studies in 2L HNSCC and 2L upper GI adenocarcinoma cancers are underway, with initial data readouts expected in mid-2026.
EX-99.1 · filed · SEC filing
After
Stated timing: 2H 2026
The Phase 1b dose-optimization studies evaluating tagmokitug in combination with toripalimab in second-line head and neck squamous cell carcinoma (HNSCC) and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in 2H 2026.
SEC original · filed · SEC filing
Data as of . Both sentences are quoted from the SEC filings linked above and matched to them.
Source: ORION, orionbiotechai.com/changes/CHRS-tagmokitug-toripalimab-2026-08-05, data as of Oct 13, 2026
https://www.orionbiotechai.com/changes/CHRS-tagmokitug-toripalimab-2026-08-05
Coherus Oncology (CHRS) pipeline and stated timing · Calendar · Companies A–Z